PRR22: A Novel Prognostic Indicator and Therapeutic Target for Prostate Cancer
PRR22 is a novel, independent prognostic biomarker and actionable therapeutic target in PRAD, linking tumor aggressiveness to immune microenvironment remodeling and drug resistance. These findings establish PRR22 as a candidate for clinical implementation in risk stratification and targeted therapy.
Authors
- Guodong Ding (ORCID: https://orcid.org/0000-0001-6576-9361)
- Qing Zhang (ORCID: https://orcid.org/0000-0002-5652-4036)
- Lao M (ORCID: https://orcid.org/0000-0001-6101-9125)
- Yiwen Chen (ORCID: https://orcid.org/0009-0003-8102-7191)
- Dongbing Li (ORCID: https://orcid.org/0000-0002-5227-9643)
- Wenxia Chen (ORCID: https://orcid.org/0000-0002-8693-5821)
- Wangdong Deng (ORCID: https://orcid.org/0009-0000-3986-6125)
- Yuantang Zhong
Institutions
- Soochow University (CN)
- Longgang Central Hospital (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2025-09-26
- DOI
- https://doi.org/10.2174/0118715206415552250910202624
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00